Clinical Research Directory
Browse clinical research sites, groups, and studies.
68Ga-B7-H3 Nanobody ImmunoPET in Osteosarcoma
Sponsor: Peking University First Hospital
Summary
This study aims to evaluate the safety, feasibility, and imaging performance of a novel 68Ga-labeled B7-H3 nanobody for immunoPET imaging in patients with osteosarcoma. Participants with suspected or histologically confirmed osteosarcoma will undergo 68Ga-B7-H3 nanobody PET/CT imaging according to the study protocol. Imaging findings will be compared with conventional imaging and, when available, histopathological results. The study will assess tracer biodistribution, tumor uptake, lesion detectability, and safety to determine the potential clinical value of B7-H3-targeted immunoPET for the diagnosis and evaluation of osteosarcoma.
Official title: Clinical Evaluation of a 68Ga-Labeled B7-H3 Nanobody for ImmunoPET Imaging in Patients With Osteosarcoma
Key Details
Gender
All
Age Range
10 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
16
Start Date
2026-04-01
Completion Date
2026-09-30
Last Updated
2026-08-19
Healthy Volunteers
No
Interventions
68Ga-B7-H3 Nanobody PET/CT
Participants with osteosarcoma will receive a single intravenous administration of the investigational 68Ga-labeled B7-H3 nanobody followed by PET/CT imaging according to the study protocol. Imaging findings will be analyzed for tracer biodistribution, tumor uptake, lesion detection, and safety.
Locations (1)
Peking University First Hospital
Beijing, Beijing Municipality, China